We are live on ! Find out more
TBPH icon

Theravance Biopharma

123 hedge funds and large institutions have $648M invested in Theravance Biopharma in 2022 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 46 increasing their positions, 27 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

126% more call options, than puts

Call options by funds: $9.48M | Put options by funds: $4.19M

77% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 13

70% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 27

14% more capital invested

Capital invested by funds: $568M → $648M (+$80.2M)

9% more funds holding

Funds holding: 113123 (+10)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

0.54% less ownership

Funds ownership: 84.39%83.85% (-0.54%)

Holders
123
Holders Change
+10
Holders Change %
+8.85%
% of All Funds
2.12%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
23
Increased
46
Reduced
27
Closed
13
Calls
$9.48M
Puts
$4.19M
Net Calls
+$5.29M
Net Calls Change
+$5.24M
Name Holding Trade Value Shares
Change
Change in
Stake
Point72 Asset Management
126
Point72 Asset Management
Connecticut
-$959K -105,900 Closed
Tudor Investment Corp
127
Tudor Investment Corp
Connecticut
-$936K -103,280 Closed
Walleye Capital
128
Walleye Capital
New York
-$775K -82,758 Closed
ZA
129
Zazove Associates
Nevada
-$540K -59,599 Closed
KWMG
130
King Wealth Management Group
Florida
-$408K -45,000 Closed
Walleye Trading
131
Walleye Trading
New York
-$136K -14,475 Closed
SOW
132
State of Wyoming
Wyoming
-$39K -4,275 Closed
CAPTRUST Financial Advisors
133
CAPTRUST Financial Advisors
North Carolina
-$1K -91 Closed
LC
134
Lindbrook Capital
California
+$66 +7 +27%
EI
135
Ellevest Inc
New York
+$122 +13 +45%

TBPH Hedge Fund Activity: Q3 2022 in Review

123 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q3 2022, worth a combined $648M — up 14% from $568M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new TBPH positions and 13 closed out — a net gain of 10 holders — while 46 added to existing stakes and 27 trimmed.

The largest buyer was Weiss Asset Management, adding an estimated $11.4M. The largest seller was Woodline Partners, cutting an estimated $19.9M.

  • 123 institutional investors held Theravance Biopharma (TBPH) as of Q3 2022, up from 113 in Q2 2022.
  • Funds reported $648M of Theravance Biopharma stock for Q3 2022, up 14% quarter-over-quarter.
  • 23 funds opened new Theravance Biopharma positions in Q3 2022 and 13 closed out, a net change of +10 holders.
  • The largest Theravance Biopharma buyer in Q3 2022 was Weiss Asset Management, an estimated $11.4M added.
  • The largest Theravance Biopharma seller in Q3 2022 was Woodline Partners, an estimated $19.9M sold.

Based on aggregated 13F filings for Q3 2022.